Outcomes Associated with the Use of Renin-Angiotensin-Aldosterone System Blockade in Hospitalized Patients with SARS-CoV-2 Infection.
Journal
Kidney360
ISSN: 2641-7650
Titre abrégé: Kidney360
Pays: United States
ID NLM: 101766381
Informations de publication
Date de publication:
Aug 2020
Aug 2020
Historique:
entrez:
21
12
2020
pubmed:
22
12
2020
medline:
22
12
2020
Statut:
ppublish
Résumé
Data regarding the benefits or harm associated with the continuation of Angiotensin Converting Enzyme Inhibitors (ACEIs) and Angiotensin II Receptor Blockers (ARBs), especially the impact on inflammation, in hypertensive, hospitalized patients with COVID-19 in the United States is unclear. This is a single-center cohort study of sequentially hospitalized patients with COVID-19 at Stony Brook University Medical Center from March 7, 2020 to April 1, 2020, inclusive of these dates. Data collection included history of known comorbidities, medications, vital signs and laboratory values (admission and during the hospitalization). Outcomes include inflammatory burden (composite scores for multiple markers of inflammation), acute kidney injury (AKI), admission to the intensive care unit (ICU), need for invasive mechanical ventilation, and mortality. Of the 300 patients in the study cohort, 80 patients (26.7%) had history of ACEI or ARB use prior to admission, with 61.3% (49/80) of these patients continuing the medications during hospitalization. Multivariable analysis revealed that the history of ACEI or ARB use prior to hospitalization was not associated with worse outcomes. In addition, the continuation of these agents during hospitalization was not associated with an increase in adverse outcomes and predicted fewer ICU admissions (OR=0.25, 0.08-0.81) with a decrease in the severity of inflammatory burden (peak CRP (6.9±3.1mg/dl, p=0.03) and peak inflammation score (2.3±1.1unit reduction, p=0.04)). Use of ACEI or ARBs prior to hospitalization was not associated with adverse outcomes in COVID-19 and the therapeutic benefits of continuing ACEI or ARB in hospitalized patients with COVID-19 was not offset by adverse outcomes.
Sections du résumé
BACKGROUND
BACKGROUND
Data regarding the benefits or harm associated with the continuation of Angiotensin Converting Enzyme Inhibitors (ACEIs) and Angiotensin II Receptor Blockers (ARBs), especially the impact on inflammation, in hypertensive, hospitalized patients with COVID-19 in the United States is unclear.
METHODS
METHODS
This is a single-center cohort study of sequentially hospitalized patients with COVID-19 at Stony Brook University Medical Center from March 7, 2020 to April 1, 2020, inclusive of these dates. Data collection included history of known comorbidities, medications, vital signs and laboratory values (admission and during the hospitalization). Outcomes include inflammatory burden (composite scores for multiple markers of inflammation), acute kidney injury (AKI), admission to the intensive care unit (ICU), need for invasive mechanical ventilation, and mortality.
RESULTS
RESULTS
Of the 300 patients in the study cohort, 80 patients (26.7%) had history of ACEI or ARB use prior to admission, with 61.3% (49/80) of these patients continuing the medications during hospitalization. Multivariable analysis revealed that the history of ACEI or ARB use prior to hospitalization was not associated with worse outcomes. In addition, the continuation of these agents during hospitalization was not associated with an increase in adverse outcomes and predicted fewer ICU admissions (OR=0.25, 0.08-0.81) with a decrease in the severity of inflammatory burden (peak CRP (6.9±3.1mg/dl, p=0.03) and peak inflammation score (2.3±1.1unit reduction, p=0.04)).
CONCLUSION
CONCLUSIONS
Use of ACEI or ARBs prior to hospitalization was not associated with adverse outcomes in COVID-19 and the therapeutic benefits of continuing ACEI or ARB in hospitalized patients with COVID-19 was not offset by adverse outcomes.
Identifiants
pubmed: 33345195
doi: 10.34067/kid.0003792020
pmc: PMC7748256
mid: NIHMS1609386
doi:
Substances chimiques
Angiotensin Receptor Antagonists
0
Angiotensin-Converting Enzyme Inhibitors
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, U.S. Gov't, Non-P.H.S.
Langues
eng
Pagination
801-809Subventions
Organisme : BLRD VA
ID : I01 BX003698
Pays : United States
Organisme : NIDDK NIH HHS
ID : R01 DK112984
Pays : United States
Déclaration de conflit d'intérêts
DISCLOSURES The authors have no financial conflicts of interest to disclose.
Références
J Clin Invest. 2020 May 1;130(5):2620-2629
pubmed: 32217835
Lancet. 2020 May 30;395(10238):1705-1714
pubmed: 32416785
N Engl J Med. 2020 Feb 20;382(8):727-733
pubmed: 31978945
N Engl J Med. 2020 Apr 30;382(18):1708-1720
pubmed: 32109013
BMJ. 2020 Feb 19;368:m606
pubmed: 32075786
Intensive Care Med. 2020 May;46(5):846-848
pubmed: 32125452
Hypertension. 2020 Jun;75(6):1382-1385
pubmed: 32208987
Br J Pharmacol. 2020 Nov;177(21):4825-4844
pubmed: 32333398
Korean J Crit Care Med. 2017 May;32(2):154-163
pubmed: 31723629
BMJ. 2020 May 22;369:m1966
pubmed: 32444366
Ann Intern Med. 2009 May 5;150(9):604-12
pubmed: 19414839
Diabetes Metab Syndr. 2020 Jul - Aug;14(4):407-412
pubmed: 32335367
Lancet. 2020 Mar 28;395(10229):1033-1034
pubmed: 32192578
Cell. 2020 Apr 16;181(2):271-280.e8
pubmed: 32142651
N Engl J Med. 2020 Jun 18;382(25):2441-2448
pubmed: 32356628
Clin Sci (Lond). 2014 Jun;126(12):815-27
pubmed: 24593683
Eur J Prev Cardiol. 2017 Dec;24(18):1914-1924
pubmed: 28862020
Autoimmun Rev. 2020 Jul;19(7):102569
pubmed: 32376394
Lancet. 2020 Mar 28;395(10229):1054-1062
pubmed: 32171076
Nat Rev Nephrol. 2020 Jun;16(6):305-307
pubmed: 32246101
Emerg Microbes Infect. 2020 Dec;9(1):757-760
pubmed: 32228222
Hypertension. 2014 Dec;64(6):1368-1375
pubmed: 25225202
Clin J Am Soc Nephrol. 2020 May 7;15(5):714-716
pubmed: 32220930
Atherosclerosis. 2010 Mar;209(1):226-9
pubmed: 19766217
Fam Med Community Health. 2020 Apr;8(2):
pubmed: 32371463
N Engl J Med. 2020 Jun 18;382(25):2431-2440
pubmed: 32356627
Shock. 2009 May;31(5):500-6
pubmed: 18827741
Lancet Respir Med. 2020 Apr;8(4):e21
pubmed: 32171062
Circ Res. 2020 Jun 5;126(12):1671-1681
pubmed: 32302265
Nat Rev Cardiol. 2020 May;17(5):259-260
pubmed: 32139904